Compare EZGO & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EZGO | MYO |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 33.3M |
| IPO Year | 2020 | 2017 |
| Metric | EZGO | MYO |
|---|---|---|
| Price | $1.25 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | ★ 4.6M | 1.1M |
| Earning Date | 07-01-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000,000.00 |
| Revenue This Year | N/A | $9.10 |
| Revenue Next Year | N/A | $13.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40814.79 |
| 52 Week Low | $0.01 | $0.61 |
| 52 Week High | $3.30 | $2.83 |
| Indicator | EZGO | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 48.06 | 64.05 |
| Support Level | $0.10 | $0.76 |
| Resistance Level | $1.32 | N/A |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 6.42 | 80.65 |
EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.